Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview.
Schinocca C, Rizzo C, Fasano S, Grasso G, La Barbera L, Ciccia F, Guggino G. · 2021
Read Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview. by Schinocca C, Rizzo C, Fasano S, Grasso G, La Barbera L, Ciccia F, Guggino G. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7937623.txt.
Description
Schinocca and co-authors present an overview of the IL-23/IL-17 pathway in rheumatic diseases. IL-23 is a signal protein made by macrophages and dendritic cells. It drives a class of T cells to release IL-17 and other inflammatory signals. That axis protects against bacteria and fungi when it works well. When it runs too hot, it feeds chronic inflammation instead.
The overview links the axis to a string of diseases. Psoriasis and psoriatic arthritis lead the list. Ankylosing spondylitis, inflammatory bowel disease, and rheumatoid arthritis follow. Blocking the axis has become a prized goal in drug research. Trials of blockers are reviewed across these conditions. The authors say the core idea is well supported, but the full contribution of the pathway still needs study. The paper gathers the latest evidence in one place.
Catalog record
| CREATOR | Schinocca C, Rizzo C, Fasano S, Grasso G, La Barbera L, Ciccia F, Guggino G. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 105 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |